NDA 207970 · Actavis
Cabazitaxel
Cabazitaxel · Intravenous
DiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 14, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
127
21 Phase 3, 14 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CABAZITAXEL · CABAZITAXEL 60MG/6ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabazitaxel" as an intervention, any sponsor and status, largest first.
- Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01308580 · 1,200 participants · Start Apr 2011 · Primary completion Aug 2015
Drug: Cabazitaxel (XRP6258); Prednisone (or Prednisolone) · For: Prostate Cancer
Sites: Muscle Shoals, Alabama; Hot Springs, Arkansas; Anaheim, California · 172 sites in all
- Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01308567 · 1,168 participants · Start May 5, 2011 · Primary completion Sep 2015
Drug: Cabazitaxel (XRP6258); Docetaxel (XRP6976) and 1 more · For: Prostate Cancer
Sites: Muscle Shoals, Alabama; Anaheim, California; Bakersfield, California · 167 sites in all
- Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01254279 · 984 participants · Start Dec 2010 · Primary completion Dec 2014
Drug: CABAZITAXEL · For: Prostate Cancer Metastatic
Sites: Box Hill, Australia; Campbelltown, Australia; Camperdown, Australia · 165 sites in all
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapsePivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT01952223 · 761 participants · Start Dec 2013 · Primary completion Dec 2025
Drug: Cabazitaxel · For: Adenocarcinoma of Prostate; Progression of Prostate Cancer
Sites: Villejuif, France
- XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00417079 · 755 participants · Start Jan 2007 · Primary completion Sep 2009
Drug: cabazitaxel (XRP6258) (RPR116258); mitoxantrone and 1 more · For: Neoplasms; Prostatic Neoplasms
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Diegem, Belgium · 26 sites in all
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPivotal-lookingRecruiting
Karolinska InstitutetAcademic, hospital or other
NCT03903835 · 750 participants (planned) · Start Feb 1, 2019 · Primary completion Dec 2026
Drug: Enzalutamide Oral Capsule; Abiraterone Oral Tablet and 8 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Aalst, Belgium; Antwerp, Belgium; Bruges, Belgium · 32 sites in all
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07213674 · 750 participants (planned) · Start Nov 28, 2025 · Primary completion Jan 7, 2030
Drug: Xaluritamig; Abiraterone acetate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Goodyear, Arizona; Tucson, Arizona; Duarte, California · 159 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, et al. · Lancet 2021 · Clinical Trial, Phase II, Multicenter Study
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R, de Bono J, Sternberg CN, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, et al. · Lancet 2010 · Clinical Trial, Phase III, Comparative Study
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S · Future Oncol 2011 · Clinical Trial, Phase III, Randomized Controlled Trial
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, et al. · Lancet Oncol 2022 · Randomized Controlled Trial, Multicenter Study
- Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, et al. · Lancet Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Actavis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.